Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Nov
15
Today In Oncology
Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer
In Case You Missed It: Roundup From ESMO Congress 2024
Exploring Issues in Oncofertility
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo